Oaktree Acquisition Corp. III Life Sciences (OACC) Return on Equity (2025 - 2026)

Oaktree Acquisition Corp. III Life Sciences (OACC) reported Return on Equity of 0.01% for Q1 2026, up 6.81% quarter-over-quarter from 0.01% in Q4 2025.

Oaktree Acquisition Corp. III Life Sciences (OACC) Return on Equity (2025 - 2026) Analysis & Trends

Oaktree Acquisition Corp. III Life Sciences has reported Return on Equity for 2 years, with the latest figure at 0.01% in Q1 2026.

  • For the quarter ending Q1 2026, Return on Equity changed N/A year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed N/A YoY), and the FY2025 full-year result was 0.01%, changed N/A from the prior year.
  • Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
  • The five-year high for Return on Equity was 0.01% in Q3 2025, with the low at 0.01% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -0.01%
2 Berto Acquisition 312.46 Mn 312.46 Mn - -0.01%
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -0.01%
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - -0.01%
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -0.01%
6 WEN Acquisition 309.15 Mn 309.15 Mn - -0.01%
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - -0.01%
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 0.00%
9 BTC Development 262.16 Mn 262.16 Mn - 0.00%
10 Oaktree Acquisition Corp. III Life Sciences 57.34 Mn 57.34 Mn - -0.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.01%
Dec 31, 2025 -0.01%
Sep 30, 2025 -0.01%